LUNDBECK and Otsuka have welcomed the approval of Abilify Maintena (aripiprazole once-monthly long-acting injectable) for the treatment of bipolar 1 disorder.
The new indication is in addition to Abilify Maintena's previous approval for schizophrenia.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Feb 18
